Blue Earth Diagnostics

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Blue Earth Diagnostics sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials 1 currently recruiting 7 completed later-stage tilt top decile by trial count

Blue Earth Diagnostics: 9 sponsored US clinical trials, 1 recruiting.

Blue Earth Diagnostics sponsors 9 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 7 completed. 6 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Invasive Lobular Breast Carcinoma, with 1 trials.

Top-decile sponsor footprint

Blue Earth Diagnostics ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 1

[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

NCT07432633
NOT YET RECRUITING Phase 4

Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence

NCT07569926
COMPLETED Phase 4

Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy

NCT06604442
COMPLETED Phase 3

Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases

NCT04410133
COMPLETED Phase 2

Study to Establish Image Interpretation Criteria for 18F Fluciclovine PET in Detecting Recurrent Brain Metastases (PURSUE)

NCT04410367
COMPLETED Phase 3

Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence

NCT04186845
COMPLETED Phase 3

Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.

NCT04186819
COMPLETED Phase 3

18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer Treatment

NCT02680041
COMPLETED

Retrospective Observational Study Investigating Fluciclovine (18F) (FACBC)

NCT02443571

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 1
Phase 3 4
Phase 4 2

Therapeutic Areas

Invasive Lobular Breast Carcinoma 1
Prostatic Neoplasms 1
Gastric Cancer 1
Pancreatic Ductal Adenocarcinoma 1
Colorectal Cancer 1
Prostate Cancer 1
Epithelial Ovarian Cancer 1

Where Blue Earth Diagnostics enrollment is open (later-stage tilt)

1 recruiting of 9 indexed (11% open); 7 completed (78%).

Phase mix: 6 late (III/IV) vs 2 early (I/II) (later-stage heavy).

Top condition: Invasive Lobular Breast Carcinoma (1 trial), 6 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Blue Earth Diagnostics: open-pipeline peers nationwide

Peers matched on 9 registered trials and 11% open enrollment, not the therapeutic-area sidebar.

Blue Earth Diagnostics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 01020304050 0%10%20%30%40%50% Total trials Recruiting share Blue Earth Diagnostics4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi companyADC Therapeutics S.A.Adrian VellaAIDS Malignancy ConsortiumAmylyx Pharmaceuticals
Blue Earth Diagnostics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Blue Earth Diagnostics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 trials (± recruiting share)

Sponsors near 11% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Blue Earth Diagnostics page

9 registered trials is a research-attention snapshot, not an endorsement of Blue Earth Diagnostics or any single study.

  • 1 of Blue Earth Diagnostics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Invasive Lobular Breast Carcinoma is the condition Blue Earth Diagnostics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Invasive Lobular Breast Carcinoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Blue Earth Diagnostics pipeline card: 9 registered trials from official public datasets.Report a data error.